Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2022 Filed Mar 29, 2022 16:03 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
GrantCommon Stock | 4,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010502 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,846.4989 F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021. Read SEC document |
| March 27, 2022 Filed Mar 29, 2022 16:00 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantCommon Stock | 2,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010500 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,611.2194 F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 13:47 UTC |
Wengel Kathryn EDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 603 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010476 · form4.xml · derivative · entry 2 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 603 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on March 25, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on March 25, 2022. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 13:47 UTC |
Wengel Kathryn EDirector
|
Exercise / conversionCommon Stock | 603 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-010476 · form4.xml · nonDerivative · entry 1 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| March 25, 2022 Filed Mar 29, 2022 13:46 UTC |
Williams R SandersDirector
|
SaleCommon Stock | 572 | $272.98 | $156,144.56 |
DisclosureSEC source: 0001127602-22-010475 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,431 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:36 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
SaleCommon Stock | 249 | $262.21 | $65,290.29 |
DisclosureSEC source: 0001127602-22-009150 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Read SEC document |
| February 16, 2022 Filed Feb 19, 2022 01:46 UTC |
NEUPERT PETER MDirector
|
PurchaseCommon Stock | 600 | $264.57 | $158,742.00 |
DisclosureSEC source: 0001127602-22-005820 · form4.xml · nonDerivative · entry 3 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,254 F3 · price: The price of $264.57 per share represents a weighted average of purchase prices ranging from $264.49 to $264.97 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 16, 2022 Filed Feb 19, 2022 01:46 UTC |
NEUPERT PETER MDirector
|
PurchaseCommon Stock | 1,600 | $263.98 | $422,368.00 |
DisclosureSEC source: 0001127602-22-005820 · form4.xml · nonDerivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,654 F2 · price: The price of $263.98 per share represents a weighted average of purchase prices ranging from $263.38 to $264.35 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 16, 2022 Filed Feb 19, 2022 01:46 UTC |
NEUPERT PETER MDirector
|
PurchaseCommon Stock | 1,300 | $262.85 | $341,705.00 |
DisclosureSEC source: 0001127602-22-005820 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,054 F1 · price: The price of $262.85 per share represents a weighted average of purchase prices ranging from $262.18 to $263.16 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 20:05 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
SaleCommon Stock | 207 | $273.98 | $56,713.86 |
DisclosureSEC source: 0001127602-22-005446 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605.4989 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 20:03 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
SaleCommon Stock | 207 | $273.98 | $56,713.86 |
DisclosureSEC source: 0001127602-22-005445 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287.018 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 694 | $272.68 | $189,239.92 |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · nonDerivative · entry 4 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,771.9106 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 84 | $272.68 | $22,905.12 |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · nonDerivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,465.9106 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 200 | $272.68 | $54,536.00 |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · nonDerivative · entry 4 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,789.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 61 | $272.68 | $16,633.48 |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · nonDerivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:43 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 277 | $272.68 | $75,532.36 |
DisclosureSEC source: 0001127602-22-005028 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,300 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:42 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 108 | $272.68 | $29,449.44 |
DisclosureSEC source: 0001127602-22-005027 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,856 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:38 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 77 | $272.68 | $20,996.36 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,812.4989 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 105 | $272.68 | $28,631.40 |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · nonDerivative · entry 4 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,552 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 694 | $272.68 | $189,239.92 |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · nonDerivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,657 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:37 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 77 | $272.68 | $20,996.36 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,494.018 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · derivative · entry 8 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,727 Underlying: Common Stock · 2,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · derivative · entry 7 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,081 Underlying: Common Stock · 284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 2,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,549.9106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,195.9106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 680 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · derivative · entry 8 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814 Underlying: Common Stock · 680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · derivative · entry 7 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,494 Underlying: Common Stock · 187 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,050.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:43 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 940 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005028 · form4.xml · derivative · entry 5 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,706 Underlying: Common Stock · 940 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:43 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005028 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,577 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:42 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 317 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005027 · form4.xml · derivative · entry 5 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,904 Underlying: Common Stock · 317 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:42 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005027 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:38 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · derivative · entry 5 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,727 Underlying: Common Stock · 284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:38 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005020 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,889.4989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · derivative · entry 8 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,838 Underlying: Common Stock · 354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · derivative · entry 7 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,192 Underlying: Common Stock · 2,354 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:40 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 2,354 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005025 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:37 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · derivative · entry 5 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 Underlying: Common Stock · 284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:37 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,571.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantNon-qualified Stock Options · Derivative | 4,500 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · derivative · entry 6 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:48 UTC |
Caveney Brian JEVP, President of Diagnostics
|
GrantRestricted Stock Unit · Derivative | 1,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005032 · form4.xml · derivative · entry 5 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,365 Underlying: Common Stock · 1,270 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantNon-qualified Stock Options · Derivative | 1,100 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · derivative · entry 6 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:51 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 330 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005035 · form4.xml · derivative · entry 5 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,681 Underlying: Common Stock · 330 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 01:29 UTC Amendment |
Williams R SandersDirector
|
GrantRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005193 · form4a.xml · derivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 742 Underlying: Common Stock · 742 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest fully on February 11, 2023. F3 · derivative.exercise_date: This form is being amended solely to correct the vesting schedule, which was previously reported incorrectly due to an administrative error. F2 · derivative.expiration_date: The Restricted Stock Units vest fully on February 11, 2023. F3 · derivative.expiration_date: This form is being amended solely to correct the vesting schedule, which was previously reported incorrectly due to an administrative error. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:43 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantNon-qualified Stock Options · Derivative | 7,700 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005028 · form4.xml · derivative · entry 4 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:43 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
GrantRestricted Stock Unit · Derivative | 2,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005028 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,646 Underlying: Common Stock · 2,170 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:42 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantNon-qualified Stock Options · Derivative | 5,100 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005027 · form4.xml · derivative · entry 4 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 5,100 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:42 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
GrantRestricted Stock Unit · Derivative | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005027 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,221 Underlying: Common Stock · 1,450 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.